title: [Prevalence of symptoms of anxiety and depression in patients with psoriatic arthritis attending rheumatology clinics].
abstract: FUNDAMENTAL AND OBJECTIVE: Psychological impairment is frequent in patients with rheumatic diseases. The aim of the study was to assess the prevalence of symptoms of anxiety and depression in patients with psoriatic arthritis attending rheumatology clinics.
  
  
  METHODS
  Multicentre cross-sectional study conducted in rheumatology clinics. Patients with psoriatic arthritis were recruited; variables retrieved were sociodemographic, clinical and patient centered (Hospital Anxiety and Depression scale o HADs, EQ-5D questionnaire, etc.). Prevalence in the study population was calculated as anxiety or depression symptoms by an HADs score ≥11 or those receiving pharmacological treatment. A logistics regression model was used to know which variables were related to symptoms of anxiety or depression.
  
  
  RESULTS
  A total of 495 patients were included, 42.8% were women and median (SD) age was 50.4 (12.7) years. Prevalence of symptoms of anxiety were 29.7% and prevalence of symptoms of depression was 17,6%. Patients with anxiety or depression symptoms had all EQ-5D dimensions affected (p<0.01). Higher prevalence of anxiety was related to being a woman, a mixed onset pattern with respect to peripheral joints and those treated with DMARD alone with respect to DMARD+NSAID or biologic alone. A higher depression prevalence was related to being a woman and a mixed onset pattern with respect to peripheral joints.
  
  
  CONCLUSIONS
  The prevalence of anxiety symptoms and the prevalence of depression symptoms are high among patients suffering psoriatic arthritis in the studied population.
authors.affiliation: Hospital Juan Canalejo, A Coruña, España.
authors.forename: Mercedes
authors.initials: M
authors.lastname: Freire
authors.forename: Jesús
authors.initials: J
authors.lastname: Rodríguez
authors.forename: Ingrid
authors.initials: I
authors.lastname: Möller
authors.forename: Antonio
authors.initials: A
authors.lastname: Valcárcel
authors.forename: Carmelo
authors.initials: C
authors.lastname: Tornero
authors.forename: Gemma
authors.initials: G
authors.lastname: Díaz
authors.forename: Yolanda
authors.initials: Y
authors.lastname: Armendáriz
authors.forename: Silvia
authors.initials: S
authors.lastname: Paredes
mesh_terms: D000328:Adult; D000368:Aged; D018501:Antirheumatic Agents / Q000627:therapeutic use; D001007:Anxiety / Q000453:epidemiology*; D001008:Anxiety Disorders / Q000453:epidemiology*; D015535:Arthritis, Psoriatic / Q000188:drug therapy / Q000453:epidemiology / Q000523:psychology*; D003430:Cross-Sectional Studies; D003863:Depression / Q000453:epidemiology*; D003866:Depressive Disorder / Q000453:epidemiology*; D004522:Educational Status; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009790:Occupations; D010044:Outpatient Clinics, Hospital / Q000706:statistics & numerical data*; D015995:Prevalence; D012219:Rheumatology / Q000706:statistics & numerical data*; D012720:Severity of Illness Index; D012959:Socioeconomic Factors; D013030:Spain / Q000453:epidemiology
chemical_list: D018501:Antirheumatic Agents